Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:advocates_for |
informed consent required
|
| gptkbp:aims_to |
effectiveness of treatment
|
| gptkbp:allows |
acknowledged in publications
|
| gptkbp:analysis |
statistical methods used
|
| gptkbp:analyzes |
Dr. Sara A. Hurvitz
|
| gptkbp:block |
open label
|
| gptkbp:business_model |
gptkb:board_game
adhered to ethical standards |
| gptkbp:clinical_trial |
Phase III
demonstrated efficacy NC T01772472 registered with clinical trial databases |
| gptkbp:collaborations |
gptkb:healthcare_organization
involvement of multiple institutions |
| gptkbp:collection |
clinical assessments
surveys and clinical evaluations |
| gptkbp:contribution |
advancements in breast cancer treatment
|
| gptkbp:criteria |
adults with HE R2-positive breast cancer
previous treatment with T-D M1 |
| gptkbp:design |
interventional study
|
| gptkbp:duration |
up to 14 cycles
|
| gptkbp:events |
5 years
|
| gptkbp:focuses_on |
HE R2-positive breast cancer
|
| gptkbp:future_plans |
suggested based on findings
|
| https://www.w3.org/2000/01/rdf-schema#label |
KATHERINE trial
|
| gptkbp:impact |
significant in oncology field
|
| gptkbp:is_compared_to |
trastuzumab emtansine to trastuzumab
|
| gptkbp:is_protected_by |
parallel assignment
|
| gptkbp:is_studied_in |
completed
multicenter study |
| gptkbp:is_tested_for |
Phase III
|
| gptkbp:launch_date |
gptkb:2015
|
| gptkbp:location |
multiple countries
|
| gptkbp:members |
gptkb:trastuzumab
|
| gptkbp:notable_work |
contributed to medical knowledge
|
| gptkbp:outcome |
overall survival
|
| gptkbp:participants |
disease-free survival
|
| gptkbp:plot_summary |
positive impact on treatment outcomes
|
| gptkbp:population |
HE R2-positive breast cancer patients
|
| gptkbp:products |
filed with FDA
trastuzumab emtansine |
| gptkbp:provides_information_on |
influenced treatment protocols
results shared with the scientific community |
| gptkbp:publishes |
gptkb:The_Lancet_Oncology
|
| gptkbp:receives_funding_from |
gptkb:Company
supported by grants |
| gptkbp:recorded_by |
randomized controlled trial
|
| gptkbp:recruitment |
ongoing during study period
|
| gptkbp:research |
published in peer-reviewed journals
improved disease-free survival rates |
| gptkbp:research_focus |
cancer therapeutics
|
| gptkbp:result |
gptkb:2021
showed improved outcomes |
| gptkbp:safety_features |
adverse events monitoring
|
| gptkbp:scientific_goals |
improve patient care
|
| gptkbp:sponsor |
gptkb:Genentech
|
| gptkbp:student_enrollment |
approximately 1500 participants
specific inclusion and exclusion criteria |
| gptkbp:treatment |
monitored throughout the study
T-D M1 vs. standard therapy standardized for all participants |
| gptkbp:year |
gptkb:2019
gptkb:2020 |
| gptkbp:bfsParent |
gptkb:Trastuzumab_emtansine
|
| gptkbp:bfsLayer |
6
|